40 research outputs found
Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity
Importance Lower bevacizumab dosages are being used for type 1 retinopathy of prematurity, but there are limited data on long-term ocular outcomes with lower doses.
Objective To evaluate ocular outcomes at 12 monthsâ corrected age for eyes that received a dose of 0.625 mg, 0.25 mg, 0.125 mg, 0.063 mg, or 0.031 mg of bevacizumab for type 1 retinopathy of prematurity.
Design, Setting, and Participants This prospective cohort study used a masked, multicenter, phase 1 dose de-escalation study design and was conducted from April 2016 to October 2017. Study eyes were treated with a dose of 0.25, 0.125, 0.063, or 0.031 mg of bevacizumab; fellow eyes were treated with a dosage 1 level higher than the study eye. Additional treatment after 4 weeks was at investigator discretion. Data analysis occurred from November 2018 to March 2019.
Interventions Intravitreous bevacizumab injections of 0.625 mg to 0.031 mg.
Main Outcomes and Measures Visual fixation, amblyopia, alignment, nystagmus, cycloplegic refraction, and ocular examinations were assessed at 12 monthsâ corrected age as preplanned secondary outcomes. The primary outcome 4 weeks after treatment and secondary outcomes after 6 monthsâ corrected age have been previously reported.
Results Forty-six of 61 infants (75%) had a 12-month follow-up examination (46 study eyes and 43 fellow eyes; median [interquartile range] birth weight, 650 [590-760] g). Of 87 eyes with a cycloplegic refraction, 12 (14% [95% CI, 7%-27%]) had myopia of more than â5.00 D spherical equivalent; 2 (2%; [95% CI, 0%-8%]) had hyperopia greater than 5.00 D spherical equivalent; and 5 infants (11% [95% CI, 4%-24%]) had anisometropia greater than 1.50 D spherical equivalent. Abnormalities of the cornea, lens, or anterior segment were reported in 1 eye (1% [95% CI, 0%-6%]), 3 eyes (3% [95% CI, 1%-10%]), and 3 eyes (3% [95% CI, 1%-10%]), respectively. Optic nerve atrophy was identified in 11 eyes (13% [95% CI, 6%-26%]), and 1 eye (1% [95% CI, 0%-6%]) had total retinal detachment. Strabismus was reported in 13 infants (30% [95% CI, 17%-45%]), manifest nystagmus in 7 infants (15% [95% CI, 6%-29%]), and amblyopia in 3 infants (7% [95% CI, 1%-18%]). Overall, 98% of infants had central fixation in each eye (44 of 45 eyes).
Conclusions and Relevance In this study of low-dose bevacizumab, the secondary outcomes of high myopia, strabismus, retinal detachment, nystagmus, and other ocular abnormalities at 1 year were consistent with rates reported in other studies with higher dosages
A prospective study of treatments for adult-onset divergence insufficiencyâtype esotropia
Purpose
To describe 10-week and 12-month outcomes following treatment for divergence insufficiencyâtype esotropia in adults.
Methods
In this prospective observational study, 110 adults with divergence insufficiencyâtype esotropia, with a distance esodeviation measuring 2Î to 30Î and at least 25% larger at distance than near, and binocular diplopia present at least âsometimesâ at distance, were enrolled at 28 sites when initiating new treatment. Surgery, prism, or divergence exercises/therapy were chosen at the investigatorâs discretion. Diplopia was assessed at enrollment and at 10-week and 12-month outcome examinations using a standardized diplopia questionnaire (DQ). Success was defined as DQ responses of ârarelyâ or âneverâ when looking straight ahead in the distance, with no alternative treatment initiated.
Results
Of the 110 participants, 32 (29%) were prescribed base-out prism; none had received prior treatment for esotropia. Success criteria were met by 22 of 30 at 10 weeks (73%; 95% CI, 54%-88%) and by 16 of 26 at 12 months (62%; 95% CI, 41%-80%). For the 76 (68%) who underwent strabismus surgery (82% of whom had been previously treated with prism), success criteria were met by 69 of 74 at 10 weeks (93%; 95% CI, 85%-98%) and by 57 of 72 at 12 months (79%; 95% CI, 68%-88%).
Conclusions
In this study cohort, both base-out prism as initial therapy and strabismus surgery (usually following prism) were successful in treating diplopia for most adults with divergence insufficiencyâtype esotropia when assessed during the first year of follow-up
Crop pests and predators exhibit inconsistent responses to surrounding landscape composition
The idea that noncrop habitat enhances pest control and represents a winâwin opportunity to conserve biodiversity and bolster yields has emerged as an agroecological paradigm. However, while noncrop habitat in landscapes surrounding farms sometimes benefits pest predators, natural enemy responses remain heterogeneous across studies and effects on pests are inconclusive. The observed heterogeneity in species responses to noncrop habitat may be biological in origin or could result from variation in how habitat and biocontrol are measured. Here, we use a pest-control database encompassing 132 studies and 6,759 sites worldwide to model natural enemy and pest abundances, predation rates, and crop damage as a function of landscape composition. Our results showed that although landscape composition explained significant variation within studies, pest and enemy abundances, predation rates, crop damage, and yields each exhibited different responses across studies, sometimes increasing and sometimes decreasing in landscapes with more noncrop habitat but overall showing no consistent trend. Thus, models that used landscape-composition variables to predict pest-control dynamics demonstrated little potential to explain variation across studies, though prediction did improve when comparing studies with similar crop and landscape features. Overall, our work shows that surrounding noncrop habitat does not consistently improve pest management, meaning habitat conservation may bolster production in some systems and depress yields in others. Future efforts to develop tools that inform farmers when habitat conservation truly represents a winâwin would benefit from increased understanding of how landscape effects are modulated by local farm management and the biology of pests and their enemies
Crop pests and predators exhibit inconsistent responses to surrounding landscape composition
The idea that noncrop habitat enhances pest control and represents a winâwin opportunity to conserve biodiversity and bolster yields has emerged as an agroecological paradigm. However, while noncrop habitat in landscapes surrounding farms sometimes benefits pest predators, natural enemy responses remain heterogeneous across studies and effects on pests are inconclusive. The observed heterogeneity in species responses to noncrop habitat may be biological in origin or could result from variation in how habitat and biocontrol are measured. Here, we use a pest-control database encompassing 132 studies and 6,759 sites worldwide to model natural enemy and pest abundances, predation rates, and crop damage as a function of landscape composition. Our results showed that although landscape composition explained significant variation within studies, pest and enemy abundances, predation rates, crop damage, and yields each exhibited different responses across studies, sometimes increasing and sometimes decreasing in landscapes with more noncrop habitat but overall showing no consistent trend. Thus, models that used landscape-composition variables to predict pest-control dynamics demonstrated little potential to explain variation across studies, though prediction did improve when comparing studies with similar crop and landscape features. Overall, our work shows that surrounding noncrop habitat does not consistently improve pest management, meaning habitat conservation may bolster production in some systems and depress yields in others. Future efforts to develop tools that inform farmers when habitat conservation truly represents a winâwin would benefit from increased understanding of how landscape effects are modulated by local farm management and the biology of pests and their enemies
Retinal nerve fiber layer thickness in amblyopic eyes
To compare the peripapillary retinal nerve fiber layer (RNFL) thickness of amblyopic and fellow eyes. We hypothesized that the RNFL of the amblyopic eye may be thinner.
Prospective, cross-sectional, observational case series.
Optical coherence tomography of the peripapillary RNFL thickness of amblyopic and fellow eyes was performed in 37 patients 7 to 12 years of age (mean age +/- standard deviation, 9.2 +/- 1.5 years) with unilateral strabismic, anisometropic, or combined-mechanism amblyopia enrolled in a randomized treatment trial.
Mean global RNFL thickness of the amblyopic and fellow eyes was 111.4 and 109.6 microm, respectively (mean difference, 1.8 microm thicker in the amblyopic eyes; 95% confidence interval, -0.6 to 4.3 microm). The amblyopic eye was 8 microm or more thicker than the fellow eye in 9 patients (24%); the fellow eye was 8 microm or more thicker than the amblyopic eye in 2 patients (5%); and the difference was within test-retest variability (7 microm) in 26 patients (70%).
Our findings do not indicate that peripapillary RNFL thickness is thinner in eyes with moderate amblyopia compared with their fellow eyes
Recommended from our members
Tonic pupil after botulinum toxin-A injection for treatment of esotropia in children
A total of 27 children with esotropia (mean age, 3.9 years; range, 9 months to 13.8 years) were enrolled in a 9-month observational study following botulinum toxin A (BTX-A) injection of one (n = 7) or both (n = 20) medial rectus muscles. BTX-A dosage ranged from 3.0 to 6.0 units per muscle. Three participants developed tonic pupil, noted at the first follow-up visit, occurring 12-19 days after injection. All 3 cases occurred in the left eye of participants who underwent bilateral BTX-A injection by the same surgeon. Anisocoria diminished from a maximum of 4 mm at the 2-week visit to 1-2 mm in all patients over the 9-month postinjection data collection period. No adverse visual outcomes were noted. Tonic pupil is an infrequently reported complication of BTX-A injection for strabismus. The experience of our investigator group suggests the need for careful injection technique and thorough preinjection counseling
Visual acuity through Bangerter filters in nonamblyopic eyes
To describe the amount of visual acuity degradation induced by Bangerter filters in the better seeing eye and to evaluate its stability over time in children with moderate amblyopia.
Visual acuity with and without a Bangerter filter was measured in the nonamblyopic eye of 186 children with moderate amblyopia who were then treated with either patching or the Bangerter filters. A 0.2 filter was used for amblyopia of 20/80 and a 0.3 filter for amblyopia from 20/40 to 20/63. For the 89 children randomized to Bangerter filters, visual acuity was also measured in the nonamblyopic eye with and without the filters at both 6 weeks and 12 weeks after initiating treatment.
Mean degradation in visual acuity of the nonamblyopic eye at baseline was 5.1 logMAR lines with the 0.2 filter and 4.8 logMAR lines with the 0.3 filter. The degradation with each filter did not always agree with the manufacturer's specifications. Over time, the amount of degradation with the filters decreased.
The 0.2 and 0.3 Bangerter filters degrade nonamblyopic eye visual acuity sufficiently in amblyopic children. Because the amount of degradation decreases over time, it is recommended to periodically apply a new filter when using this type of amblyopia treatment
Assessment of Pediatric Optic Neuritis Visual Acuity Outcomes at 6 Months
Importance: Optic neuritis (ON) in children is uncommon. There are limited prospective data for visual acuity (VA) outcomes, associated diseases, and neuroimaging findings. Prospective data from a large sample would be useful for counseling families on treatment decisions and prognosis.
Objective: To prospectively study children with a first episode of ON, describe VA after 6 months, and ascertain the network's (Pediatric Eye Disease Investigator Group and Neuro-Ophthalmology Research Disease Investigator Consortium) ability to enroll pediatric patients with ON prospectively.
Design, setting, and participants: This nonrandomized cohort study was conducted from September 20, 2016, to July 20, 2018, at 23 sites in the United States and Canada in pediatric ophthalmology or neuro-ophthalmology clinics. A total of 44 children (aged 3-15 years) presented with a first episode of ON (visual loss, pain on eye movements, or both) within 2 weeks of symptom onset and at least 1 of the following in the affected eye: a distance high-contrast VA (HCVA) deficit of at least 0.2 logMAR below age-based norms, diminished color vision, abnormal visual field, or optic disc swelling. Exclusion criteria included preexisting ocular abnormalities or a previous episode of ON.
Main outcomes and measures: Primary outcomes were monocular HCVA and low-contrast VA at 6 months. Secondary outcomes were neuroimaging, associated diagnoses, and antibodies for neuromyelitis optica and myelin oligodendrocyte glycoprotein.
Results: A total of 44 children (mean age [SD], 10.2 [3.5] years; 26 boys [59%]; 23 White individuals [52%]; 54 eyes) were enrolled in the study. Sixteen patients (36%) had bilateral ON. Magnetic resonance imaging revealed white matter lesions in 23 children (52%). Of these children, 8 had myelin oligodendrocyte glycoprotein-associated demyelination (18%), 7 had acute disseminated encephalomyelitis (16%), 5 had multiple sclerosis (11%), and 3 had neuromyelitis optica (7%). The baseline mean HCVA was 0.95 logMAR (20/200), which improved by a mean 0.76 logMAR (95% CI, 0.54-0.99; range, -0.70 to 1.80) to 0.12 logMAR (20/25) at 6 months. The baseline mean distance low-contrast VA was 1.49 logMAR (20/640) and improved by a mean 0.72 logMAR (95% CI, 0.54-0.89; range, -0.20 to 1.50) to 0.73 logMAR (20/100) at 6 months. Baseline HCVA was worse in younger participants (aged <10 years) with associated neurologic autoimmune diagnoses, white matter lesions, and in those of non-White race and non-Hispanic ethnicity. The data did not suggest a statistically significant association between baseline factors and improvement in HCVA.
Conclusions and relevance: The study network did not reach its targeted enrollment of 100 pediatric patients with ON over 2 years. This indicates that future treatment trials may need to use different inclusion criteria or plan a longer enrollment period to account for the rarity of the disease. Despite poor VA at presentation, most children had marked improvement by 6 months. Associated neurologic autoimmune diagnoses were common. These findings can be used to counsel families about the disease
Recommended from our members
Stereoacuity in children with anisometropic amblyopia
PURPOSE: To determine factors associated with pretreatment and posttreatment stereoacuity in subjects with moderate anisometropic amblyopia. METHODS: Data for subjects enrolled in seven studies conducted by the Pediatric Eye Disease Investigator Group were pooled. The sample included 633 subjects aged 3 to <18 years with anisometropic amblyopia, no heterotropia observed by cover test, and baseline amblyopic eye acuity of 20/100 or better. A subset included 248 subjects who were treated with patching or Bangerter filters and had stereoacuity testing at both the baseline and outcome examinations. Multivariate regression models identified factors associated with baseline stereoacuity and with outcome stereoacuity as measured by the Randot Preschool Stereoacuity test. RESULTS: Better baseline stereoacuity was associated with better baseline amblyopic eye acuity (P < 0.001), less anisometropia (P = 0.03), and anisometropia due to astigmatism alone (P < 0.001). Better outcome stereoacuity was associated with better baseline stereoacuity (P < 0.001) and better amblyopic eye acuity at outcome (P < 0.001). Among 48 subjects whose amblyopic eye visual acuity at outcome was 20/25 or better and within one line of the fellow eye, stereoacuity was worse than that of children with normal vision of the same age. CONCLUSIONS: In children with anisometropic amblyopia of 20/40 to 20/100 inclusive, better posttreatment stereoacuity is associated with better baseline stereoacuity and better posttreatment amblyopic eye acuity. Even if their visual acuity deficit resolves, many children with anisometropic amblyopia have stereoacuity worse than that of nonamblyopic children of the same age
A Randomized Trial of Increasing Patching for Amblyopia
Le 9 mai 2007, François Morel nous quittait Ă lâĂąge de 84 ans, aprĂšs toute une vie consacrĂ©e Ă la recherche sur la physiologie rĂ©nale quâil a rĂ©alisĂ©e en grande partie au CollĂšge de France oĂč il a Ă©tĂ© titulaire de la chaire de Physiologie cellulaire de 1967 Ă 1993. François Morel Ă©tait nĂ© Ă GenĂšve en 1923. Son pĂšre Ă©tait titulaire de la chaire de Psychiatrie dans cette ville, ce qui lâa sans doute incitĂ© Ă entreprendre des Ă©tudes de mĂ©decine. En fait, il nâa jamais exercĂ© la mĂ©decine car, trĂš..